Estimating the Threshold Surface Density of Gp120-CCR5 Complexes
                    Necessary for HIV-1 Envelope-Mediated Cell-Cell Fusion by Mulampaka, Shiva Naresh & Dixit, Narendra M.
Estimating the Threshold Surface Density of Gp120-CCR5
Complexes Necessary for HIV-1 Envelope-Mediated Cell-
Cell Fusion
Shiva Naresh Mulampaka
1, Narendra M. Dixit
1,2*
1Department of Chemical Engineering, Indian Institute of Science, Bangalore, India, 2Bioinformatics Centre, Indian Institute of Science, Bangalore, India
Abstract
Reduced expression of CCR5 on target CD4
+ cells lowers their susceptibility to infection by R5-tropic HIV-1, potentially
preventing transmission of infection and delaying disease progression. Binding of the HIV-1 envelope (Env) protein gp120
with CCR5 is essential for the entry of R5 viruses into target cells. The threshold surface density of gp120-CCR5 complexes
that enables HIV-1 entry remains poorly estimated. We constructed a mathematical model that mimics Env-mediated cell-
cell fusion assays, where target CD4
+CCR5
+ cells are exposed to effector cells expressing Env in the presence of a coreceptor
antagonist and the fraction of target cells fused with effector cells is measured. Our model employs a reaction network-
based approach to describe protein interactions that precede viral entry coupled with the ternary complex model to
quantify the allosteric interactions of the coreceptor antagonist and predicts the fraction of target cells fused. By fitting
model predictions to published data of cell-cell fusion in the presence of the CCR5 antagonist vicriviroc, we estimated the
threshold surface density of gp120-CCR5 complexes for cell-cell fusion as ,20 mm
22. Model predictions with this threshold
captured data from independent cell-cell fusion assays in the presence of vicriviroc and rapamycin, a drug that modulates
CCR5 expression, as well as assays in the presence of maraviroc, another CCR5 antagonist, using sixteen different Env clones
derived from transmitted or early founder viruses. Our estimate of the threshold surface density of gp120-CCR5 complexes
necessary for HIV-1 entry thus appears robust and may have implications for optimizing treatment with coreceptor
antagonists, understanding the non-pathogenic infection of non-human primates, and designing vaccines that suppress the
availability of target CD4
+CCR5
+ cells.
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Introduction
The entry of HIV-1 into target cells requires the formation of
complexes between the viral envelope protein (Env) and the
cellular receptor, CD4, as well as a coreceptor, either CCR5 or
CXCR4. CCR5 appears to play a central role in HIV-1
transmission and disease progression to AIDS. Viruses transmitted
across individuals are predominantly R5 viruses, i.e., require
CCR5 for entry [1,2]. Studies of simian immunodeficiency virus
(SIV) infections of non-human primates suggest that differences in
the expression level of CCR5 on target CD4
+ cells may underlie
the difference between the non-pathogenic infection of natural
hosts, such as African green monkeys and sooty mangabeys, and
the pathogenic infection of non-natural hosts, such as rhesus
macaques [1–3]. The former have substantially lower levels of
CD4
+CCR5
+ target cells than the latter [4]. Low CCR5
expression may imply reduced susceptibility of cells to infection
[5,6]. Consequently, the extent of viral replication at mucosal sites
may be suppressed, lowering the probability of transmission.
Indeed, low CCR5 expression in newborns correlated with poor
SIV transmission via breast-feeding, which may underlie the
negligible mother-to-child transmission of infection in natural
hosts [7]. Similarly, humans homozygous for the CCR5D32 allele,
which results in complete suppression of CCR5 expression, are
extraordinarily resistant to HIV-1 infection [8]. At the same time,
low CCR5 expression may control damage to the gut mucosa,
suppressing microbial translocation, and also reduce T cell homing
to sites of inflammation, thereby lowering immune activation and
contributing to the non-pathogenic nature of infection in natural
hosts [4,9,10]. Reducing the availability of target CD4
+CCR5
+
cells therefore appears to be a promising strategy for therapeutic
and preventive vaccine development [1–3]. Indeed, the CCR5
antagonist maraviroc was found recently to protect rhesus
macaques from vaginal transmission (Veazey et al., Abstract #
84LB 17th Conference on Retroviruses and Opportunistic
Infections, 2010).
Env is a trimer of non-covalently attached extracellular gp120
and transmembrane gp41 glycoprotein heterodimers [11]. During
viral entry, gp120 first binds to CD4, following which conforma-
tional changes expose a cryptic binding site on gp120 for CCR5
[12]. Following CCR5 binding to gp120, further conformational
changes bring the viral and cell membranes into close apposition,
culminating in viral entry [12–14]. Direct observation of the
protein complexes that mediate viral entry has remained a
challenge. One strategy to overcome this limitation has been to
employ mathematical models to analyse viral infectivity assays and
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7infer the stoichiometry and/or the number of complexes necessary
for viral entry [14–21]. Following such an approach, previous
studies have argued that multiple CD4 and CCR5 molecules must
be bound to gp120 for viral entry [15,16]. More recent studies
using virions expressing heterotrimeric Env containing combina-
tions of wild-type and mutant gp120 molecules, the latter
incapable of mediating entry, suggested that a single Env trimer
with at least two functional gp120 subunits is adequate for HIV-1
entry [17,18]. When the latter experiments were reanalysed using
more detailed mathematical models, one study estimated that 5
trimers on a virion carrying 9 trimers are necessary for entry [19],
whereas another study estimated that 8 trimers (range 2–19
depending on the assumptions employed) represent the threshold
for entry [20]. Further, a model of allosteric interactions between
CCR5 and gp120 argued that the better adapted a viral strain is to
utilize CCR5, the fewer the CCR5 molecules needed for entry,
with highly adapted strains requiring a single CCR5 bound to
gp120 [14]. Robust estimates of the threshold number and the
stoichiometry of Env-CD4-CCR5 complexes necessary for HIV-1
entry are thus lacking.
Here, we developed a mathematical model that mimics cell-cell
fusion assays widely employed to investigate HIV entry into target
cells (e.g., [13,22–25]). The model employs a reaction network-
based approach to describe the protein interactions that precede
viral entry and quantitatively predicts the influence of the CCR5
expression level on the susceptibility of target cells to Env-
mediated cell-cell fusion. We applied the model to analyse data
from cell-cell fusion assays in the presence of the CCR5 antagonist
vicriviroc and obtained estimates of the threshold surface density
of gp120-CCR5 complexes necessary for cell-cell fusion. We
validated the estimate by comparison of model predictions with
independent data from cell-cell fusion assays in the presence of
rapamycin, which down-regulates CCR5 expression, as well as
assays using different Env clones in the presence of another
coreceptor antagonist, maraviroc.
Results
Model formulation
We modelled cell-cell fusion assays where target cells expressing
CD4 and CCR5 are exposed to effector cells expressing Env in the
presence of a coreceptor antagonist and the percentage of target
cells fused with effector cells is measured (e.g., see [23,24]). To
describe these assays, we first considered a single target cell-
effector cell pair in close apposition and employed reaction kinetics
to determine the surface densities of different Env-CD4-CCR5
complexes formed across the pair. The reaction network and the
rate equations are mentioned in Text S1. We found by solving the
rate equations that reaction equilibrium was attained rapidly
(,1 s) compared to the time required for cell-cell fusion (,min)
(Fig. S1). Further, for typical CD4 and Env expression levels, CD4
appeared to be in large excess so that all gp120 monomers were
bound to CD4 at equilibrium. The reaction network may
therefore be simplified by ignoring the trimeric nature of Env
and considering the total surface density of gp120 molecules as
being available for interaction with CCR5. With this simplifica-
tion, we determined the surface density of gp120-CCR5
complexes formed across a closely apposed target cell-effector cell
pair as a function of the CCR5 expression level on the target cell
(Methods). We postulated that a threshold surface density of
gp120-CCR5 complexes must be formed for cell-cell fusion. Thus,
if the surface density of gp120-CCR5 complexes formed is larger
than the threshold, the target cell-effector cell pair is fused (Fig. 1).
We next assumed that the CCR5 expression level on target cells in
a cell-cell fusion assay follows a truncated normal distribution.
Cells with smaller expression levels of CCR5 form fewer
complexes and may not fuse. We thus estimated the fraction of
cells that expresses CCR5 at levels larger than that required to
form the threshold surface density of gp120-CCR5 complexes,
which yields the fraction of cells fused in the assay.
A coreceptor antagonist typically binds to an allosteric site on
CCR5 and inhibits CCR5 binding to gp120 [26]. Consequently,
fewer gp120-CCR5 complexes are formed between a cell-cell pair
as exposure to the coreceptor antagonist increases (Fig. 1). A target
cell would therefore require higher CCR5 expression to form the
threshold surface density of gp120-CCR5 complexes when
exposed to the coreceptor antagonist. Thus, in a cell-cell fusion
assay, the fraction of cells fused decreases as the concentration of
the coreceptor antagonist increases. We employed the standard
ternary complex model to describe the gp120-CCR5 interaction
across a cell-cell pair in the presence of a coreceptor antagonist
[27]. Accordingly, we estimated the fraction of cells fused at
different levels of exposure to the antagonist (Methods). We
present model predictions below.
Model predictions
Distribution of CCR5 on target cells. In Fig. 2A, we
present the distribution, f(C0), of the CCR5 expression level, C0,o n
cells, computed using Eq. (12) (Methods), for a fixed mean
expression level C0~16mm{2, which corresponds to ,5000
molecules/cell (radius,5 mm), and different standard deviations,
sC. For small values of sC (~2mm{2 in Fig. 2A), the distribution
is nearly normal and sharply peaked at C0.A ssC increases, the
size of the peak drops and the distribution spreads over a broader
range of values of C0 centred near C0. For even larger values of sC
(~20mm{2 in Fig. 2A), because the distribution is truncated at
C0~0, the distribution spreads to larger values of C0 and is
unevenly distributed about C0.
Threshold CCR5 expression and cell-cell fusion. With
the above distribution of CCR5 expression and given a threshold
Figure 1. Schematic of the model. A) High CCR5 expression on a
target cell allows the formation of the requisite gp120-CCR5 complexes
for cell-cell fusion. B) Low CCR5 expression or C) the presence of a
coreceptor antagonist reduces the surface density of gp120-CCR5
complexes and prevents fusion.
doi:10.1371/journal.pone.0019941.g001
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0 , we computed the
fraction of cells fused in a cell-cell fusion assay, F, using Eq. (13)
(area of the shaded region in Fig. 2A (inset)). CT
0 depends on the
threshold surface density of gp120-CCR5 complexes that enables
entry, GCT (Eq. (11)). We therefore examined model predictions
of the dependence of F on GCT for different values of sC (Fig. 2B).
CT
0 increases upon increasing GCT (Fig. 2B (inset)). Thus, for a
fixed sC, increasing GCT resulted in smaller F (Fig. 2B). When
CT
0 ~GCT~0, all cells had C0wCT
0 , which implied F=1.AsCT
0
increased, a smaller fraction of cells had expression levels C0wCT
0
and F decreased. With small sC (~2mm{2 in Fig. 2), because the
distribution of CCR5 expression was sharply peaked at C0, nearly
all cells had C0wCT
0 when CT
0 was modestly smaller than C0,
whereas few cells had C0wCT
0 when CT
0 increased modestly
above C0. Consequently, F exhibited a sharp drop from 1 to 0 as
GCT increased. The drop occurred around the value of GCT at
which CT
0 ~C0. With larger sC, the wider distribution of CCR5
implied that the drop in F was gradual (sC~8mm{2 and 20mm{2
in Fig. 2). Eventually, as GCT approached G0, the expression level
of gp120 on effector cells, CT
0 rose sharply (Fig. 2B (inset)) because
of the limitation in the availability of gp120. Correspondingly, F
dropped sharply as GCT approached G0 (=20:46mm{2 in
Fig. 2B).
Gp120-CCR5 interactions in the presence of a coreceptor
antagonist. We next predicted the equilibrium surface densities
of the various reacting species across a single target cell-effector
cell pair (Eq. 5), calculated using Eqs. (6)–(9), as functions of the
concentration of the coreceptor antagonist, A0, for different values
of the cooperativity factor, a (Fig. 3). (KA and A0 always appear as
their product in the model equations, so that changes in KA have
the same effect as changes in A0.) a is the ratio of the binding
affinities of the antagonist for gp120-bound CCR5 and unbound
CCR5 (Eq. 5). For fixed a, as we increased A0, we found that the
surface density of unbound gp120, G, increased implying that
fewer CCR5 molecules bound to gp120. At the same time, the
surface densities of free CCR5 and gp120-CCR5 complexes, C
and GC, respectively, decreased, whereas the surface densities of
their antagonist bound counterparts, AC and AGC, increased,
indicating greater binding of the antagonist to CCR5. Higher
values of a imply greater affinity of the antagonist for gp120-bound
CCR5. Accordingly, for fixed A0, increasing a resulted in
increased AGC, and decreased surface densities of all the other
species. Thus, increasing A0 or decreasing a resulted in fewer
CCR5 molecules binding gp120.
Cell-cell fusion in the presence of a coreceptor
antagonist. In Fig. 4, we present the fraction of target cells
fused, FA 0 ðÞ , and the inhibition of fusion, IA 0 ðÞ , calculated using
Eqs. (3)–(16), as functions of A0, for different values of GCT and a.
For fixed GCT and a, we found that, as expected, increasing A0
lowered FA 0 ðÞ and increased IA 0 ðÞ . When A0~0, FA 0 ðÞ ~F,
predicted above in the absence of the drug (Fig. 2B). Increasing A0
resulted in fewer gp120-CCR5 complexes, which lowered FA 0 ðÞ
and increased IA 0 ðÞ . For very large values of A0, all CCR5
molecules were bound to the antagonist. Yet, because, according
to the ternary complex model, the antagonist when bound to
CCR5 lowers but does not annihilate the ability of CCR5 to bind
gp120, gp120-CCR5 complexes formed even when all the CCR5
molecules were bound to the antagonist. Further, because we
assumed that antagonist-bound CCR5 may also trigger fusion
when bound to gp120, a fraction of cells, with sufficiently high
expression levels of CCR5, fused even when A0 was very large.
For given A0 and a, increasing GCT resulted in lower FA 0 ðÞ
because the threshold expression level CT
0 (A0) increased with
GCT and fewer cells had expression levels C0wCT
0 (A0).
Accordingly, IA 0 ðÞ also increased with GCT. For fixed GCT
and A0,a sa increased, greater binding of gp120 to antagonist-
bound CCR5 increased FA 0 ðÞ and consequently decreased IA 0 ðÞ .
Our model thus describes the outcome of a cell-cell fusion assay
in the presence of a coreceptor antagonist. Below, we present
comparisons of our predictions with experiments.
Comparisons with experiments
Estimation of the threshold surface density of gp120-
CCR5 complexes. Recently, Heredia et al. [24] performed cell-
cell fusion assays to examine the antiviral activity of vicriviroc, a
CCR5 antagonist in phase III trials (Gathe et al., Abstract # 45LB
17th Conference on Retroviruses and Opportunistic Infections,
2010). They performed the assays with and without rapamycin, a
drug that lowers the expression level of CCR5 on cells [6]
(Methods). We fit our prediction of F(A0) to their data of the
percentage of cells fused as a function of vicriviroc concentration
in the absence of rapamycin using three adjustable parameters,
Figure 2. Model predictions of cell-cell fusion in the absence of a coreceptor antagonist. A) Distribution, f(C0), of the CCR5 expression
level, C0, across cells, predicted using Eq. (12), for the mean expression, C0~16mm{2 and different values of the standard deviation, sC. Inset:
Fraction of cells fused, F, is the (shaded) area under the f(C0) curve for C0wCT
0 , the threshold CCR5 expression level for fusion. B) F as a function of
GC
T, the threshold surface density of gp120-CCR5 complexes necessary for fusion. Inset: The dependence of CT
0 on GC
T computed using Eq. (11).
doi:10.1371/journal.pone.0019941.g002
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(Fig. 5A). The best-fit parameter estimates (95% confid-
ence intervals) were GCT~20:41(20:38{20:45)mm{2, sC~
7:7(5:9{9:6)mm{2, and a~0:09(0:03{0:14). The best-fit
estimate of GCT&20mm{2 gives the minimum surface density
of gp120-CCR5 complexes that must be formed between apposed
cells for the cells to fuse. Further, using the best-fit value of GCT in
Eq. (11), we obtained CT
0 ~21:4mm{2, which yields the minimum
expression level of CCR5 on target cells expressing excess CD4
that can fuse with effector cells with the gp120 expression level
G0&20mm{2. The latter minimum expression level corresponds
to ,6700 CCR5 molecules/cell (radius,5 mm).
Validation of best-fit parameter estimates. To validate
our parameter estimates, we compared our model predictions with
independent data of cell-cell fusion as a function of vicriviroc
concentration in the presence of rapamycin, reported by Heredia
et al. [24]. Rapamycin lowers the mean expression level of CCR5
on target cells, C0, in a dose-dependent manner [6]. Using the
above best-fit parameter estimates, we therefore fit model
predictions to the data of Heredia et al. [24] using C0 as an
adjustable parameter. Our model provided good fits to the data
(Fig. 5B) and yielded estimates of C0 that are in close agreement
with measurements, presenting a successful validation of our
model and parameter estimates. Thus, for rapamycin levels of 0.1,
0.3, and 1 nM, we obtained C0 (95% CI) as 4300 (4100–4400),
3700 (3500–4000), and 2100 (1000–3200) molecules/cell, whereas
experimental measurements of the mean CCR5 expression
levels under the same conditions were 3900, 3535, and 2791,
respectively [24].
Robustness of best-fit parameter estimates. The above
experiments have employed the HIV-1 JRFL Env. Also,
rapamycin is known to have a cytostatic effect on cells [6], the
influence of which on cell-cell fusion remains unknown. To test the
robustness of our parameter estimates, we therefore examined
additional experiments on cell-cell fusion reported by Hu et al.
[28] that employed a wide variety of Env clones derived from
transmitted or are early founder viral genomes [29]. The
experiments were performed in the presence of maraviroc, a
Figure 3. Predictions of the ternary complex model. Equilibrium surface densities of A) unbound gp120, G, B) unbound CCR5, C, C) gp120-
CCR5 complexes, GC, D) CCR5-coreceptor antagonist complexes, AC and E) gp120-CCR5-coreceptor antagonist complexes, AGC, as functions of the
concentration of the coreceptor antagonist, A0, for different values of the cooperativity factor, a, calculated by solving Eqs. (6)–(9).
doi:10.1371/journal.pone.0019941.g003
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cell-cell fusion relative to that in the absence of maraviroc was
reported (Methods). We compared our predictions of the relative
extent of cell-cell fusion, 100{I(A0), as a function of maraviroc
concentration with the observations of Hu et al. [28] for 16
different Env clones. To describe this data, we employed the
affinity of maraviroc for CCR5, KA=1.15 nM
21 [30], and let the
cooperativity factor, a, which is unknown for maraviroc, be an
adjustable parameter. We also employed the threshold surface
density of gp120-CCR5 complexes, GCT, as an adjustable
parameter to examine the dependence of this threshold on
variations in the HIV-1 Env. Our model provided good fits to all
the 16 data sets (Fig. 6). The best-fit values of GCT and a are
presented in Table 1. We found that a varied substantially across
the different Env clones (range: 0.002–0.13) indicating varying
degrees of sensitivity to maraviroc, in agreement with the
conclusions of Hu et al. [28]. The varying sensitivity was also
evident from the corresponding values of IC50 (range:
approximately 14–1300 nM), which we obtained for each clone
as the maraviroc concentration at which the relative extent of
fusion was 50% (Table 1). Interestingly, GCT appeared to be
nearly constant across the clones (19:8+0:7mm{2) and close to
the value estimated above (*20mm{2) indicating the robustness
of the latter estimate. That nearly the same value of GCT captured
multiple experimental data sets with different HIV-1 Env clones in
the presence of two different coreceptor antagonists and an agent
that altered CCR5 expression levels suggests that our model
captures the cell-cell fusion assays accurately and gives us
confidence in our estimate of the threshold surface density of
gp120-CCR5 complexes necessary for cell-cell fusion.
Discussion
The role of CCR5 in mediating HIV-1 entry has important
implications for HIV-1 transmission and disease progression to
AIDS as well as for strategies of intervention [1–3]. Yet, the
threshold surface density of CCR5 molecules that must interact
with gp120 to facilitate HIV-1 entry remains poorly estimated.
Here, we constructed a mathematical model to analyse data from
cell-cell fusion assays and estimated the threshold surface density
of gp120-CCR5 complexes that enables HIV-1 Env-mediated cell-
cell fusion. We found the threshold surface density of gp120-
CCR5 complexes to be *20mm{2. The corresponding minimum
expression level of CCR5 on target cells that allows cell-cell fusion
given the gp120 expression level on effector cells employed in our
analysis and when CD4 is not limiting is *21:4mm{2, equivalent
Figure 4. Model predictions of cell-cell fusion in the presence
of a coreceptor antagonist. The fraction of cells fused, F(A0), as a
function of the concentration of the coreceptor antagonist for A)
different values of GC
T with a=0.01 and B) different values of a with
GC
T=20mm{2 computed using Eqs (1)–(15). C) and D) The correspond-
ing inhibition of fusion due to the coreceptor antagonist calculated
using Eq. (16). The standard deviation of the CCR5 expression level,
sC~8:76mm{2.
doi:10.1371/journal.pone.0019941.g004
Figure 5. Comparisons of model predictions with experiments.
A) Fit of model predictions of F(A0) (line) to published experimental data
[24] (symbols) of the fraction of cells fused as a function of vicriviroc
concentration using C0~17mm{2 (=5318 molecules/cell [24]) and with
GCT, a, and sC as adjustable parameters. The other parameters are
mentioned in Methods. The dashed lines are 95% confidence limits on
the predictions. Inset: Difference between model predictions and the
experimental data; the mean error is 0.002 (in units of the percentage of
cells fused) and is not significantly different from zero (P=0.996 using a
two-tailed t-test). B) Fits of model predictions of F(A0) (lines) to data [24]
(symbols) of the fraction of cells fused as a function of vicriciroc
concentration in the presence of different concentrations of rapamycin
(RAPA) using C0 as an adjustable parameter. The other parameters are
the same as in A). The best-fit parameter estimates are mentioned in
the text.
doi:10.1371/journal.pone.0019941.g005
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we analysed data from independent cell-cell fusion experiments
performed in the presence of vicriviroc and maraviroc, both
CCR5 antagonists, and rapamycin, a drug that down-regulated
CCR5 expression, as well as with sixteen different Env clones
derived from transmitted or early founder viruses. Our model
provided good fits to the data and yielded an estimate of the
threshold surface density of gp120-CCR5 complexes that
remained nearly constant at *20mm{2 across these experiments,
indicating the robustness of our estimate.
Our estimate of the threshold surface density of gp120-CCR5
complexes necessary for HIV-1 entry may facilitate optimal
utilization of coreceptor antagonists for preventive and therapeutic
intervention. For instance, the estimate suggests that a potent
coreceptor antagonist must reduce the surface density of gp120-
CCR5 complexes to below *20mm{2. CCR5 expression levels
vary substantially across individuals, with mean levels in the range
,1000 to ,10000 molecules/cell [31]. The variations may be due
at least in part to variations in the CCL3L1 gene copy number,
which was recently observed to be correlated with the suscepti-
Figure 6. Robustness of model predictions. Fits of model predictions (lines) of the relative extent of cell-cell fusion, 1002I(A0), as a function of
maraviroc concentration to published experimental observations [28] (symbols) using KA~1:15 nM
21 and with a and GCT as adjustable parameters.
The other parameters are mentioned in Methods. The different panels represent data from experiments using different Env clones (legends). The best
fits (solid lines) and the corresponding 95% confidence limits (dashed lines) are shown. The best-fit parameter estimates are mentioned in Table 1.
doi:10.1371/journal.pone.0019941.g006
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larger mean CCR5 expression levels would require greater drug
exposure to achieve the same level of inhibition [33]. Our model
may be applied to estimate the necessary drug exposure and may
thus serve to personalize the usage of coreceptor antagonists based
on the CCR5 expression level and/or the CCL3L1 gene dose in
patients. Maraviroc was recently found to prevent transmission in
rhesus macaques in a dose dependent manner when employed as a
vaginal microbicide (Veazey et al., Abstract # 84LB 17th
Conference on Retroviruses and Opportunistic Infections, 2010).
CCR5 expression levels on target CD4
+ T cells in mucosal regions
may be higher than in peripheral blood [34]. Consequently,
greater exposure to a coreceptor antagonist in mucosal regions
may be necessary to prevent transmission than is necessary in
plasma during treatment. Our model may again serve to quantify
this greater exposure. Similarly, for vaccine strategies that aim to
reduce the availability of target CD4
+CCR5
+ cells at sites of
transmission [1,2], our study suggests that CCR5 expression must
be lowered to a level that restricts the formation of gp120-CCR5
complexes to below *20mm{2 in order to prevent infection of
target cells.
Our study may also inform the substantial ongoing efforts to
elucidate the origins of the differences between SIV infection of
natural and non-natural hosts (reviewed in [1–3]). An intriguing
hypothesis explaining the non-progressive infection of natural
hosts despite high plasma viral loads hinges on the reduced
susceptibility of the central memory cell compartment in these
animals due to low CCR5 expression [2]. In contrast, in non-
natural hosts, the central memory compartment may be depleted
more rapidly because of higher CCR5 expression levels. In both
natural and non-natural hosts, the activated and effector memory
cells have high CCR5 levels and are responsible for high plasma
viral loads. The threshold expression level of CCR5 that renders
target cells susceptible to SIV infection remains unknown. Our
model may be applied to analyse data from SIV-Env-mediated
cell-cell fusion assays and estimate the corresponding threshold
CCR5 expression level for SIV infection, which may serve to
elucidate the differences between natural and non-natural hosts of
SIV. Indeed, more generally, our model provides a framework for
analysing cell-cell fusion assays, widely employed to investigate
HIV entry and related intervention strategies.
Recent studies have argued that the mechanism of viral entry
into cells may be distinct from cell-cell fusion: while cell-cell fusion
involves membrane fusion at the cell surface, HIV-1 entry appears
to involve receptor and coreceptor mediated endocytosis [35,36].
Following endocytosis, however, the viral membrane fuses with the
endosomal membrane facilitating the release of viral contents into
the cytoplasm leading to productive infection [35,36]. Thus, if the
membrane fusion processes are similar in cell-cell fusion and viral-
endosomal fusion, which remains to be ascertained, the same
threshold surface density of gp120-CCR5 complexes may underlie
both cell-cell fusion and viral infection of target cells.
We recognize approximations in our model that hold for cell-
cell fusion but may not apply to viral entry in vivo. First, our
model describes the protein interactions that precede viral entry
using a continuum, mass action-based approach. Such a
continuum approximation is expected to be accurate for cell-
cell fusion, where the number of protein molecules per cell is
large (.10
3). The advantage of the continuum approach is the
simplicity of the resulting model equations and their facile
application to data analysis. With virus-cell interaction, however,
because virions express far fewer gp120 molecules (1467E n v
trimers per virion [37]), a stochastic description may be more
appropriate (see, e.g., [38]). Second, our model considers the
Table 1. Threshold surface density of gp120-CCR5 complexes for different Env clones.
Env clone
Threshold complex surface
density, GC
T (mm
22) Cooperativity factor, a IC50 (nM)
RHPA.A19.2000 19.9 (19.5–20.2) 0.011 (0.005–0.031) 79.5
PRB958_06.TB1.4305 19.6 (18.6–20.1) 0.009 (0.002–0.026) 242.1
PRB926_04.A9.4237 20.2 (20.1–20.3) 0.021 (0.012–0.033) 29.0
6244_13.B5.4576 20.0 (18.7–20.4) 0.020 (0.003–0.130) 143.3
1054.TC4.1499 20.1 (19.3–20.3) 0.020 (0.005–0.058) 100.9
62357_14.D3.4589 20.1 (20.0–20.2) 0.015 (0.009–0.021) 44.4
9021_14.B2.4571 20.2 (19.3–20.4) 0.028 (0.005–0.100) 71.4
1006_11.C3.1601 20.1 (19.7–20.3) 0.013 (0.005–0.030) 46.0
6240_08.TA5.4622 19.7 (18.5–20.2) 0.013 (0.004–0.040) 798.5
SC05.8C112344 20.3 (18.2–20.5) 0.082 (0.003–0.741) 1287.0
700010058.A4.4375 19.4 (16.4–20.2) 0.005 (0.001–0.030) 201.1
REJO.D12.1972 20.4 (20.2–20.5) 0.128 (0.032–0.473) 17.6
PRB931_06.TC3.4930 18.3 (17.4–19.0) 0.002 (0.001–0.004) 469.8
SC45.4B5.2631 17.8 (16.7–18.5) 0.002 (0.001–0.003) 699.3
62615_03.P4.3964 20.3 (19.5–20.4) 0.042 (0.007–0.200) 43.2
700010040.C9.4520 20.4 (20.3–20.4) 0.061 (0.038–0.096) 13.9
Mean 19.8 0.030 267.9
Estimates of the threshold surface density of gp120-CCR5 complexes, GC
T, and the cooperativity factor, a, for 16 different transmitted or early founder viruses
determined from fits of model predictions with experimental data [28] of cell-cell fusion in the presence of maraviroc (Fig. 6). 95% confidence intervals for the best-fit
parameter estimates are shown in brackets. The corresponding IC50 values of maraviroc are also listed.
doi:10.1371/journal.pone.0019941.t001
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CD4 and gp120 levels. This approximation is reasonable for
analysis of cell-cell fusion assays in the presence of coreceptor
antagonists, which effectively lower the availability of CCR5 for
binding gp120 and render CD4 and gp120 not limiting. With
viral entry, however, a distribution of Env trimers is observed
[37] and may have to be accounted for to accurately describe the
susceptibility of target cells in vivo [20]. Further, where CD4 is
down-modulated, as in African green monkeys [39], the
assumption that all gp120 molecules are bound to CD4 and
therefore accessible to CCR5 may not hold and the complete
network of Env-CD4-CCR5 interactions (Text S1) may have to
be considered. Indeed, cells with low CD4 expression have been
suggested to require high CCR5 for infection [40]. Nonetheless,
because the above approximations are expected to hold for the
cell-cell fusion assays we analysed, they may not confound our
estimate of the threshold surface density of gp120-CCR5
complexes necessary for viral entry.
The spatial distribution of CCR5 across the surface of a target
cell and its role on viral entry remains to be established. While one
study suggests that CCR5 molecules are localized within lipid rafts
[41], another finds CCR5 molecules in non-raft regions [42].
Several studies suggest that CCR5 is colocalized and/or associated
with CD4 [41,43,44]. Although CD4 is preferentially localized
within rafts, such localization may not be essential for viral entry
[45]. At the same time, membrane cholesterol depletion, which is
known to affect raft formation and may also influence CCR5
mobility [46], inhibits viral entry when the receptors are not
expressed in excess [41,42,47]. Current studies thus leave unclear
the spatial distribution of CCR5 and its role in HIV-1 entry. Here,
as an approximation, therefore, we have assumed CCR5 to be
randomly distributed on the target cell surface. Further, effector
cells have been suggested to recruit CCR5 to regions of cell-cell
contact [41], the mechanisms underlying which remain unknown.
Only recently have studies begun to unravel the local organization
of protein complexes in the virus-cell contact region, which may be
important for viral entry [38,48,49]. A quantitative assessment of
the impact of the latter phenomena on estimates of the threshold
surface density of gp120-CCR5 complexes necessary for viral
entry awaits further studies that would establish the spatial
distribution of CCR5 on target cells and of the mechanisms that
underlie receptor migration and recruitment following virus-cell
contact.
Finally, we note that our model assumed that each gp120
monomer in an Env trimer is independently accessible to CCR5.
In contrast, steric constraints may result in increasingly hindered
successive binding of CCR5 to the second and third gp120
monomers of an Env trimer. Conversely, cooperative binding
may render successive binding easier [14]. Besides, recent single-
molecule studies suggest that a complex energy landscape
underlies gp120-CD4-CCR5 interactions [50,51], the implica-
tions of which for viral entry remain to be fully understood.
Further, heterogeneity in the CCR5 molecules, arising, for
instance, due to post-translational modifications [52], may
introduce additional variations in the affinity of CCR5 for
gp120. Nonetheless, by assuming that all gp120 monomers are
equally accessible to CCR5, our model ignores the association of
gp120 into trimers and precludes identification of the stoichiom-
etry of the Env-CD4-CCR5 complexes that renders the
complexes fusion competent. At the threshold surface density,
gp120-CCR5 complexes would be distributed such that some
Env trimers are bound to 3 CCR5 molecules, some to 2, some to
1 and some to none (Fig. S1). It is possible that only Env trimers
bound to 2 or more CCR5 molecules, for instance, mediate entry.
While our model can be extended to predict this latter
distribution (Text S1), currently available data does not allow
establishment of the stoichiometry of CCR5 binding to Env that
enables entry [20].
Methods
Data
We have analysed experimental data of HIV-1-Env mediated
cell-cell fusion published recently by Heredia et al. [24] and Hu
et al. [28]. In the cell-cell fusion assays reported by Heredia et al.
[24], lymphocytes expressing CD4 and CCR5 (target cells) were
treated with different concentrations of rapamycin and coincubated
with 293T cells transfected with HIV-1 JRFL Env (effector cells) for
2.5 h at 37uC in the presence of known concentrations of vicriviroc.
The two cell types were stained with different fluorescent dyes. Flow
cytometry was used to detect cell-cell fusion: cells that were positive
for both dyes indicated a fusion event. The fraction of target cells
that eventually fused was reported as a function of vicriviroc
concentration for different levels of exposure to rapamycin.
In the experiments performed by Hu et al. [28], QT6 cells
transfected with CD4 and CCR5 (target cells) were exposed to QT6
cells transfected with HIV-1 Env expression constructs (effector
cells) in the presence of different concentrations of maraviroc. The
target cells were also transfected with a luciferase construct under
the transcriptional control of T7 promoter. Luciferase activity was
measured ,8 h following co-incubation and reported as a
percentage of the activity in the absence of maraviroc, thus
representing the extent of inhibition of cell-cell fusion due to
maraviroc. The experiments were performed using different Env
Table 2. Summary of model parameters and their values employed.
Parameter Description Value
a Source
G0 Surface density of gp120 on effector cells 20:5mm{2 [22], see text
C0 Mean surface density of CCR5 on target cells 16mm{2 [24], see text
sC Standard deviation of the surface density of CCR5 across cells 7:7mm{2 Best-fit (Fig. 5A)
KC Equilibrium association constant of gp120 with CCR5 412mm2 [53], see text
GCT Threshold surface density of gp120-CCR5 complexes 20mm{2 Best-fits (Figs. 5 and 6, Table 1)
a Cooperativity factor in the ternary complex model (Eq. (5)) 0.03 Best-fits (Fig. 6, Table 1)
KA Equilibrium association constant of a coreceptor antagonist with CCR5 1:15nM{1 [30]
aTypical values; variations are indicated in the text and in figure legends.
doi:10.1371/journal.pone.0019941.t002
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strains [29]. Hu et al. reported cell-cell fusion data for 18 different
clones of which two were found to be highly resistant to maraviroc
[28]. Here, we analysed data for the remaining 16 clones.
Mathematical model
Single target cell-effector cell pair. We considered first the
interactions between proteins across a single target cell-effector cell
pair in the absence of a coreceptor antagonist (Fig. 1). Typically,
CD4 molecules are in excess and rapidly bind all available gp120
molecules in the contact region on an apposed effector cell, as
shown by our detailed reaction kinetics calculations (Text S1) and
by independent simulations of virus-cell interactions [49]. We
therefore considered the interactions between gp120 and CCR5:
GzC / { { ?
kon
koff
GC ð1Þ
Here, G, C, and GC are the surface densities (numbers per unit
area) of gp120, CCR5, and gp120-CCR5 complexes, respectively.
Eq. (1) assumes that each gp120 molecule in an Env trimer is
bound to CD4 and is independently accessible to CCR5. The
reaction in Eq. (1) attains equilibrium rapidly compared to fusion;
equilibrium is attained within seconds (Fig. S1), whereas the lag
time for fusion is in minutes [22]. At equilibrium, the surface
densities of the reacting species obey
KC:C:G~GC ð2Þ
where KC~kon=koff is the equilibrium association constant of
CCR5 with gp120. If the effector cell expresses G0 gp120
molecules per unit area (i.e., G0=3 Env trimers per unit area) and
the target cell C0 CCR5 molecules per unit area, then species
balance implies
G~G0{GC
C~C0{GC
ð3Þ
where changes in the protein surface densities due to protein
diffusion in and out of the cell-cell contact region are assumed
negligible (see Discussion). Combining Eqs. (2) and (3) resulted in a
quadratic equation in GC, solving which we obtained
GC~
1
2
G0zC0z
1
KC
{
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
G0zC0z
1
KC
   2
{4G0C0
s 2
4
3
5 ð4Þ
Eq. (4) yields the surface density of CCR5 bound to gp120
between a single target cell-effector cell pair.
Threshold CCR5 binding for cell-cell fusion. We defined
GC
T as the minimum surface density of gp120-CCR5 complexes
that must be formed between a target cell-effector cell pair for the
cells to fuse. Thus, the cell pair fuses if GC$GC
T.
Single target cell-effector cell pair in the presence of a
coreceptor antagonist. We next considered a single target cell-
effector cell pair in the presence of a CCR5 antagonist, A,a t
concentration A0. We employed the standard ternary complex
model to describe the resulting allosteric interactions [27]:
Here, gp120 can bind to a complex of CCR5 and A, denoted AC,
with an altered binding affinity aKC, where a is the cooperativity
factor. Similarly, A can bind to GC with affinity aKA, where KA is
the affinity of the antagonist for CCR5. At equilibrium, the
ternary complex model yields
KC:G:C~GC
KA:A:C~AC
aKC:G:AC~aKA:A:GC~AGC
ð6Þ
along with the species balance equations
C0~CzGCzACzAGC
G0~GzGCzAGC
ð7Þ
We assumed that the concentration of A does not decrease
substantially below A0 . Combining Eqs. (6) and (7) yielded a
quadratic equation in C, C0~C(1zKAA0)zC(1zaKAA0)
KCG0=(1zKCCzaKAKCA0C), which we solved to obtain
C~
C0{G0
2(1zKAA0)
{
1
2(1zaKAA0)KC
z
C0{G0
2(1zKAA0)
{
1
2(1zaKAA0)KC
   2 "
z
C0
(1zKAA0)(1zaKAA0)KC
 1=2
ð8Þ
Eqs. (6) and (7) also imply
G~G0=(1zKCCzaKAKCA0C) ð9Þ
using which in Eq. (6) along with Eq. (8), we obtained the surface
densities of all the reacting species in the ternary complex model.
In particular, the surface density of CCR5 bound to gp120,
GCzAGC~KC:G:CzaKCKA:G:A0:C ð10Þ
For fusion, this latter surface density must be larger than the
threshold surface density, GCT.
Cell-cell fusion assay. In a cell-cell fusion assay, target cells
with different expression levels of CCR5 form different surface
densities of gp120-CCR5 complexes at equilibrium. We defined
CT
0 as that expression level of CCR5 that would result in the
formation of the threshold surface density, GCT, of complexes. In
the absence of a coreceptor antagonist, from Eqs. (2) and (3), it
follows that
CT
0 ~GCTz
GCT
KC(G0{GCT)
ð11Þ
Because GC increases with C0 (Eq. (4)), all cells with C0wCT
0 will
fuse with effector cells. On the other hand, all cells with C0vCT
0
will be unable to fuse. We assumed next that the expression level of
CCR5 on cells follows a truncated normal distribution with mean
C0 and standard deviation sC,
(5)
Threshold Gp120-CCR5 Complexes for HIV-1 Entry
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19941f(C0)~
ﬃﬃﬃ
2
p
r exp {
C0{C0 ðÞ
2
2s2
C
  
sCerfc {
C0 ﬃﬃ
2
p
sC
   ð12Þ
where f(C0)dC0 represents the fraction of cells with the CCR5
expression level within a small range dC0 near C0, and
erfc z ðÞ ~
2
ﬃﬃﬃ
p
p
ð ?
z
exp({t2)dt is the complementary error function.
Note that
ð ?
0
f(C0)dC0~1. The fraction of target cells that fuses,
F, is then the fraction of cells with C0wCT
0 , i.e.,
ð ?
CT
0
f(C0)dC0,
which upon substituting for f(C0) from Eq. (12) yielded
F~
erfc
CT
0 {C0 ﬃﬃﬃ
2
p
sC
  
erfc {
C0 ﬃﬃﬃ
2
p
sC
   : ð13Þ
Equation (13) predicts the fraction of cells fused in a cell-cell fusion
assay in the absence of a coreceptor antagonist.
Cell-cell fusion assay in the presence of a coreceptor
antagonist. In the presence of the coreceptor antagonist, the
expression level of CCR5 that results in the formation of complexes at
the surface density GCT would be higher than CT
0 because the
coreceptor antagonist inhibits the binding of CCR5 with gp120. We
defined CT
0 (A0) as that expression level of CCR5 that would result in
the formation of the threshold surface density, GCT,o fc o m p l e x e si n
the presence of the coreceptor antagonist at concentration A0.W e
obtained CT
0 (A0) as that value of C0 that satisfies
GCzAGC~KC:G:CzaKCKA:G:A0:C~GCT ð14Þ
The fraction of cellsthat fuses, F(A0),i st h e nt h ef r a c t i o no fc e l l sw i t h
C0wCT
0 (A0), i.e.,
F(A0)~
erfc
CT
0 (A0){C0 ﬃﬃ
2
p
sC
  
erfc {
C0 ﬃﬃ
2
p
sC
   : ð15Þ
Equation (15) predicts the fraction of target cells fused in a cell-cell
fusion assay in the presence of a coreceptor antagonist. Note that Eq.
(15) reduces to Eq. (13) when A0~0. The percentage of inhibition of
cell-cell fusion due to the coreceptor antagonist is then
I(A0)~(1{
F(A0)
F
):100 ð16Þ
Parameter estimates
We performed model calculations using parameter estimates
representative of the cell-cell fusion assays we considered [24]
unless mentioned otherwise. Target cells employed in the assays
were lymphocytes from donors, with CCR5 expression levels in
the range 2000–7000 molecules/cell [24]. We therefore assumed
the mean CCR5 expression level on cells, C0~16mm{2,
corresponding to ,5000 molecules/target cell (radius,5 mm).
We set the expression level of gp120 on the effector cells,
G0~20:46mm{2, equivalent to ,10000 Env trimers/effector cell
(radius,10 mm), following observations of ,2 ng of gp120 on
,10
6 effector cells [22]. The equilibrium dissociation constant of
gp120 binding to CCR5 is ,4 nM [53]. The corresponding
affinity when both gp120 and CCR5 are restricted to membranes,
following the analysis of Bell [54] and assuming an encounter
radius of 0.75 nm,i sKC~412mm2 (Text S1). The affinity of
vicriviroc for CCR5, KA~1:25 nM
21 [55]. The cooperativity
factor, a, and the standard deviation of the CCR5 expression level
on cells, sC, are not known and we estimated them along with the
threshold surface density of complexes, GCT, by fitting model
predictions to data. The parameters employed are summarized in
Table 2.
Model calculations and comparisons with experiments
We solved the above equations and fit model predictions to data
using a computer program written in MATLAB. We employed the
inbuilt routine NLINFIT, which uses the Levenberg-Margquardt
algorithm for nonlinear least squares, for fitting model predictions
to data and for obtaining 95% confidence intervals. For some of
the data sets of transmitted/founder Env-mediated cell-cell fusion
in the presence of maraviroc, NLINFIT yielded confidence
intervals that included negative parameter values. We therefore
determined 95% confidence intervals on the best-fit parameter
values for the transmitted/founder Env-mediated cell-cell fusion
data sets by performing 200 bootstrap replicates each, again in
MATLAB.
Supporting Information
Figure S1 Time-evolution of the surface densities of the
species in the reaction network. Surface densities of the
species in the network (Eq. (1) in Text S1), namely, (A) unbound
Env and Env molecules bound to single CD4 molecules, (B) Env
bound to 2 CD4 molecules, (C) Env bound to 3 CD4 molecules,
and (D) unbound CD4 and CCR5, obtained by solving Eq. (2) in
Text S1 (solid lines), and of the equilibrium surface densities of
CCR5 and the gp120-CCR5 complexes in the simplified network
(Eq. (5) in Text S1) (dashed lines), obtained by solving Eqs. (6)–(9)
in Text S1. Parameter values and initial conditions are mentioned
in Text S1. All surface densities are normalized with the initial Env
surface density.
(TIF)
Text S1 Detailed kinetics of Env-CD4-CCR5 binding. A
detailed description of the kinetics of the Env-CD4-CCR5 binding
across a target cell-effector cell pair is presented.
(DOC)
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